Skip to contentB
BioCardia, Inc.
B
BCDABioCardia, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derived−100.0% vs Q4 2023 Net Income-$2.30M-$2.30MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioCardia, Inc. · CIK 925741 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$2,321,000N/M Operating Cash Flowderived-$2,433,000N/M Free Cash Flowderived-$2,434,000N/M ended Dec 31, 2024 · filed Mar 26, 2025 · 85 d after period end